← Leaderboards
Huei-Ting Tsai
Georgetown University
$519,182
Attributed
$519,182
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $144.7K · FY2012–16$200K$150K$100K$50K$0
'12
'13
'14
'15
'16
Funding mix
By agency
AHRQ$368,655 · 1
NIH$150,527 · 1
By mechanism
K01$368,655 · 1
R03$150,527 · 1
Top collaborators
No co-investigators on record.
Most similar at Georgetown University
Same institution · by research overlap
- Bjorn C Knollmann$24,293,199
- Arnold L Potosky$11,589,176
- Vanessa B Sheppard$7,900,849
- Kathryn L Taylor$9,804,663
- Claudine Isaacs$8,250,667
Others in their field
Top investigators on “Accounting”
- Gary D Acton · University Of California-Davis$320,373,312
- Mitchell J Malone · Texas A&M Research Foundation$320,373,312
- Charles Mattias Mountain · Association Of Universities For Research In Astronomy, Inc.$185,928,938
- Zeljko Ivezic · University Of Washington$142,654,512
- Victor Krabbendam · Association Of Universities For Research In Astronomy, Inc.$142,654,512
- Steven M Kahn · Association Of Universities For Research In Astronomy, Inc.$142,654,512
Research focus
AccountingAcute Myocardial InfarctionAdoptionAdverse EventAgedAgonistAndrogensBaseCancer DiagnosisCancer PatientCancer SurvivorCardiac DeathCaringCharacteristicsClinicClinical PracticeClinical TrialsCohortCohort StudiesCommunitiesComparativeComparative EffectivenessDatabasesAcademic Medical Centers
Grant awards (5)
Comparative Effectiveness Study of Hormonal Therapy in Advanced Prostate Cancer$87,309
K01 · FY2016 · HS · contact PI
Comparative Effectiveness Study of Hormonal Therapy in Advanced Prostate Cancer$144,677
K01 · FY2015 · HS · contact PI
Comparative Effectiveness Study of Hormonal Therapy in Advanced Prostate Cancer$136,669
K01 · FY2014 · HS · contact PI
USE AND OUTCOMES OF INTERMITTENT ANDROGEN DEPRIVATION THERAPY IN PROSTATE CANCER$73,027
R03 · FY2013 · CA · contact PI
USE AND OUTCOMES OF INTERMITTENT ANDROGEN DEPRIVATION THERAPY IN PROSTATE CANCER$77,500
R03 · FY2012 · CA · contact PI